For decades, women who survived early breast cancer have carried an unspoken fear alongside their recovery: that the treatments which saved them might one day summon a second illness. A landmark English study tracking nearly half a million women over twenty years now offers a measured answer to that fear — the elevated risk of a second primary cancer is real, but modest, amounting to only two or three percentage points above what the general population faces. In placing that number beside the substantial benefits of treatment, the research invites survivors and clinicians alike to weigh uncert
Early breast cancer patients face low second cancer risk, study finds
The long-term risk is real but modest, and it should not deter women from pursuing treatments that offer substantial benefit.
Mark
When you say the risk is "low," what does that actually mean for someone sitting in a doctor's office hearing they have breast cancer?
Mimi
It means that if you're treated and survive, the chance that cancer will come back as something entirely different—or on the other side of your chest—is small enough that it shouldn't dominate your decision about whether to accept treatment. You're trading a certain threat now for a modest one later.
Mark
But 2 to 3 percent more than the general population—that's not nothing. Over millions of women, that's real harm.
Mimi
True. And the researchers aren't hiding that. But context matters. A woman at 60 already has a 15 percent baseline risk of cancer by 80. Adding 2 percent to that is different from adding 2 percent to zero. The absolute numbers are what should move you.
Mark
The study mentions radiotherapy causes more contralateral breast cancer. Doesn't that suggest we should use less radiation?
Mimi
It does suggest we should be thoughtful about it. But remember—7 percent of the excess cancers come from treatment at all. The cancer you're treating now is almost certainly more dangerous than the small risk you're taking on. The researchers are saying: yes, there's a cost, but it's worth it.
Mark
What about the gaps in the data—family history, genetics, smoking? Could those change the picture?
Mimi
They could shift the numbers somewhat. Someone with a strong family history of cancer might face different odds than the average woman in the study. But the study is still the most complete picture we have of what actually happens to hundreds of thousands of real women over decades.
Mark
So what does a patient do with this information?
Mimi
They can have a clearer conversation with their doctor. They know the risk isn't theoretical anymore—it's measured. And they know it's small enough that the benefits of treatment almost always win.
Le Pouls
- For years, inconsistent estimates left breast cancer survivors and their doctors navigating treatment decisions without a reliable map of long-term second-cancer risk.
- A study of 476,373 women — one of the largest and longest of its kind — has now produced the clearest picture yet: a 2–3% excess risk over two decades, far smaller than many feared.
- Specific therapies carry specific footprints: radiotherapy raises lung and contralateral breast cancer risk, endocrine therapy is linked to uterine cancer, and chemotherapy carries a small leukaemia signal.
- Yet treatment-related cancers account for only about 7% of the excess risk observed, meaning the vast majority of elevated risk stems from factors beyond the therapies themselves.
- The research lands as a reassurance — not a dismissal of risk, but a grounding of it in numbers concrete enough to support honest, informed conversations between patients and clinicians.
For decades, women who survived early breast cancer have carried an unspoken fear alongside their recovery: that the treatments which saved them might one day summon a second illness. A landmark English study tracking nearly half a million women over twenty years now offers a measured answer to that fear — the elevated risk of a second primary cancer is real, but modest, amounting to only two or three percentage points above what the general population faces. In placing that number beside the substantial benefits of treatment, the research invites survivors and clinicians alike to weigh uncertainty with greater clarity and less dread.
Nearly half a million English women treated for early breast cancer have now been followed long enough to answer one of survivorship's most persistent questions: does treatment plant the seeds of a future cancer? Research published in the British Medical Journal offers a reassuring, if carefully qualified, reply. Women diagnosed with early invasive breast cancer face only a 2 to 3 percent greater risk of developing a second primary cancer than women in the general population — a modest elevation that researchers say should ease the minds of patients weighing their options.
The study drew on data from 476,373 women aged 20 to 75 treated in England between 1993 and 2016, with follow-up stretching across two decades. Of these women, 64,747 developed a second primary cancer. Non-breast cancers — chiefly womb, lung, and bowel — appeared in 13.6 percent of survivors, a 2.1 percent excess over the general population. Contralateral breast cancer occurred in 5.6 percent, a 3.1 percent excess. To make this tangible: a woman diagnosed at 60 faces roughly a 17 percent risk of a non-breast cancer by age 80, compared to 15 percent for a woman without prior breast cancer.
Certain treatments were tied to specific risks — radiotherapy to lung and contralateral breast cancers, hormone therapy to uterine cancer, chemotherapy to a small leukaemia signal. But the authors stress that these treatment-related cases account for only around 7 percent of the excess cancers observed, and that the benefits of these therapies overwhelmingly outweigh the added risk in nearly every case where they are recommended.
The study acknowledges gaps — incomplete registry data, no information on family history, genetics, or lifestyle factors like smoking. Still, its scale and duration make it the most complete picture yet assembled. Where clinicians and patients once pieced together risk from fragmented, inconsistent evidence, they now have something closer to a full answer: the long-term risk is genuine, but it is modest enough that it should not stand between a woman and the treatment most likely to save her life.
Nearly half a million English women with early breast cancer have now been tracked long enough to answer a question that has haunted survivors for decades: what are the real odds that treatment will lead to another cancer down the road? The answer, according to research published in the British Medical Journal, is reassuring. Women diagnosed with early invasive breast cancer face only a 2 to 3 percent greater risk of developing a second primary cancer compared to women in the general population—a modest elevation that researchers say should ease the minds of patients weighing their treatment options.
The study drew on data from 476,373 women aged 20 to 75 who were treated for early breast cancer in England between 1993 and 2016. Over the course of up to two decades of follow-up, 64,747 of these women developed a second primary cancer. The researchers found that while breast cancer survivors do face elevated risk, the difference between their outcomes and those of the general population is smaller than previous, inconsistent estimates had suggested. This clarity matters. For years, clinicians and patients have operated with uncertainty about the true magnitude of this risk, making it harder to have honest conversations about the trade-offs involved in treatment.
The excess risk breaks down into two categories. Non-breast cancers—predominantly womb, lung, and bowel cancers—appeared in 13.6 percent of the breast cancer survivors, representing a 2.1 percent increase over what would be expected in women without a prior breast cancer diagnosis. Contralateral breast cancer, which develops on the opposite side of the body, occurred in 5.6 percent of cases, a 3.1 percent excess compared to the general population. To make these numbers concrete: a woman diagnosed at age 60 faces an estimated 17 percent risk of developing a non-breast cancer by age 80, compared to 15 percent for a woman of the same age without prior breast cancer. For contralateral breast cancer, the figures are 5 percent versus 2 percent. The gap narrows for younger women. A 40-year-old survivor faces a 6 percent risk of a second cancer by age 60, compared to 4 percent for non-breast and 2 percent for contralateral breast in the general population.
The researchers identified specific treatments as contributors to particular second-cancer risks. Radiotherapy was linked to higher rates of contralateral breast and lung cancers. Endocrine therapy—hormone treatment—was associated with uterine cancer. Chemotherapy carried a small increased risk of acute leukaemia. Yet the authors emphasize that these treatment-related risks account for only about 7 percent of the excess second cancers observed, and they stress that the benefits of these therapies in treating the initial cancer substantially outweigh the small additional risk in nearly all cases where they are recommended.
The study has limitations. Cancer registry data was incomplete for some variables, and the researchers lacked information on family history, genetic predisposition, and lifestyle factors like smoking—all of which could influence second-cancer risk. Despite these gaps, the authors describe their work as providing a detailed and accurate picture of second-cancer development across a complete population of early breast cancer patients tracked for up to 20 years. That completeness is rare. Most previous studies were smaller or followed patients for shorter periods, leaving clinicians and patients to piece together risk estimates from fragmented evidence. This research offers something closer to a full answer: the long-term risk is real but modest, and it should not deter women from pursuing treatments that offer substantial benefit against their initial cancer.
Citations marquantes
The benefits of adjuvant therapies outweigh the small risk of second cancer in almost all circumstances where these treatments are recommended.— Study authors, British Medical Journal
Envie de l'histoire complète ?
Lire l'original sur The Irish Times ↗
Health & Medicine